The biosimilar patent dance isnt a formalityits the first move in a multi‑year chess match.
If youre a biologics innovator or a biosimilar applicant, the stakes are obvious: exclusivity, market timing, and the ability to launch on schedule. Whats l…

Generic winners dont wait for exclusivitythey engineer it.
In the Paragraph IV world, 180-day exclusivity is often described like a prize at the end of a race. But the real story is less about luck and more about execution: timing, litigation strateg…

The Patent Dance Is No Longer a ChoreographyIts a Strategy War. Heres the Playbook.
If youve been anywhere near biologics and biosimilars over the last few years, you already know the script: the patent dance under the BPCIA is supposed to bring clarit…

Big Pharma loves to talk about pipelines. But the real competitive edge is increasingly hiding in the supply chainspecifically in the data that predicts what will be available, when, and at what cost.
Thats the thesis behind a new piece from DrugPatent…

Patent cliffs arent just a legal eventtheyre a supply-chain event.
If youre responsible for sourcing, procurement, or commercial planning in pharma, you already know the headline: when patents expire, competition arrives fast, prices can drop, and fo…

Generic drug makers are supposed to be the industrys steady enginelower prices, faster access, and predictable margins. But lately, predictable has gone out the window. In a world where patents, pricing pressure, and supply-chain realities collide, gen…

Branded pharmas revenue model is under siegeand its not just one problem. Its a stack of brutal, compounding forces that are quietly turning steady growth into constant defense.
In a recent DrugPatentWatch piece, the argument is blunt: the branded phar…

Generic drug entry isnt just about scienceits about timing.
If youve ever wondered how some generic manufacturers consistently beat the clock and others get stuck in regulatory limbo, the answer often lives in a place most people never read: the FDAs…

Biopharma hiring is broken in a way that looks strategic on paper.
Most teams build IP portfolios like theyre standalone assetsthen wonder why the organization cant translate those assets into faster decisions, cleaner diligence, or smarter partnering….

The generic cliff doesnt hit anymoreits engineered around.
For years, the story of drug patents was simple: a blockbuster wins, exclusivity ends, generics arrive, revenue falls off a cliff. But the modern playbook in pharma is less about waiting for …